目的 觀察伏格列波糖聯(lián)合利拉魯肽治療2型糖尿病的臨床療效。方法 選取無棣縣人民醫(yī)院2015年10月-2016年9月接診的2型糖尿病患者106例，隨機分為對照組和治療組，每組各53例。對照組皮下注射利拉魯肽注射液，起始劑量為0.6 mg/d，1周后增至1.2 mg/d，1次/d；治療組在對照組的基礎(chǔ)上口服伏格列波糖片，0.2 mg/次，3次/d。兩組患者均治療12周。比較治療前后兩組患者臨床療效、血糖和血脂指標(biāo)水平改善情況。結(jié)果 治療后，對照組臨床總有效率為81.13%，顯著低于治療組的94.34%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者空腹血糖（FPG）、早餐后2 h血糖（2 h PG）和糖化血紅蛋白等血糖指標(biāo)，以及三酰甘油（TG）、膽固醇（CHO）和低密度脂蛋白（LDL-C）等血脂指標(biāo)水平均顯著下降，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者血糖、血脂指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 伏格列波糖聯(lián)合利拉魯肽治療2型糖尿病臨床療效顯著，可明顯改善化驗指標(biāo)，且不良反應(yīng)較少，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical curative effect of voglibose combined with liraglutide in treatment of type 2 diabetes. Methods Patients (106 cases) with type 2 diabetes in Wudi People's Hospital from October 2015 to September 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were subcutaneous injection administered with Liraglutide Injection, the initial dosage was 0.6 mg/d, and increased to 1.2 mg/d after one week, once daily. Patients in the treatment group were po administered with Voglibose Tablets on the basis of the control group, 0.2 mg/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, clinical efficacy, and the improvement of blood glucose and serum lipid levels in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 81.13%, which was significantly lower than 94.34% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the fasting blood glucose, 2 h blood sugar after breakfast and glycosylated hemoglobin of the blood glucose indexes, and the serum lipid levels of TG, CHO and LDL-C in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of blood glucose and serum lipid in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Voglibose combined with liraglutide has satisfactory clinical efficacy in treatment of type 2 diabetes, can significantly improve laboratory indexes with less adverse reactions, which has a certain clinical application value.